Analysis of Cost-Effectiveness of Biologic Therapies in Axial Spondyloarthritis Based on Real-World Data
Biologic therapies are cost-effective for patients with axSpA, especially those not achieving clinical targets. Patients' selection, and targeted cost-containment strategies, such as biosimilars and medication price reductions, can enhance clinical benefits and reduce societal costs.
Authors
- Nasir Elsidig
- Ahmed Negm (ORCID: https://orcid.org/0000-0002-3849-6852)
- Ahlam Almarzooqi (ORCID: https://orcid.org/0000-0001-6169-7284)
- Jamal Al Saleh (ORCID: https://orcid.org/0000-0002-7569-003X)
- Noura Zamani (ORCID: https://orcid.org/0009-0006-9035-0363)
Institutions
- Al-Azhar University (EG)
- Oasis Hospital (AE)
- Dubai Hospital (AE)
Publication Details
- Journal
- ClinicoEconomics and Outcomes Research
- Published
- 2025-12-01
- DOI
- https://doi.org/10.2147/ceor.s556012
- Primary Topic
- Spondyloarthritis Studies and Treatments
- Type
- article
- Field-Weighted Citation Impact
- 0.00